Form 4 for GILD Gilead Sciences
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-10 · accession 0001127602-24-009544 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-11 | 2024-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | F - Tax | $75.12 | -13.8K | 484.8K | -3% | -$1.04M |
| DM | 2024-03-11 | 2024-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | +29.9K | 498.6K | +6% | — |
| DM | 2024-03-11 | 2024-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | A - Grant | $0.00 | +334.0K | 279.1K | New | $0 |
| DM | 2024-03-11 | 2024-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | -29.9K | 100.1K | -23% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-10 | F | D | 13,782 | $75.12 | 484,847 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-10 | M | A | 10,800 | — | 479,489 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 3 | Common | Common Stock | 2024-03-10 | M | A | 19,140 | — | 498,629 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 4 | Derivative | Restricted Stock Unit | 2024-03-10 | A | A | 54,910 | — | 135,862 | D | — · — to — | 54,910 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 5 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 19,140 | — | 80,952 | D | — · — to — | 19,140 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-03-10 | A | A | 279,130 | $0.00 | 279,130 | D | $75.12 · — to 2034-03-10 | 279,130 Common Stock | (F4) The options have a four-year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 10,800 | — | 100,092 | D | — · — to — | 10,800 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. |